Track your comments!
[x]


When you register, comments on your articles and replies to your comments appear here. Register Now!

Sign in to your account
[x]

Not a Scientific Blogging member yet?

Register Now for a Free Scientificblogging.com Account

  • Customize your profile with pictures, banner, a blogroll and more.
  • Leave comments on articles, add other members to your friend lists, chat with people on the site.
  • Write blog posts that can be seen by hundreds of thousands of readers.

It's free and it only takes a minute!

Already a Scientific Blogging member?

Sign In Now

Banner
By Michael White | September 24th 2008 09:13 PM | 3 comments | Print | E-mail | Track Comments
.

More Adaptive Complexity articles

All

About Michael White

Welcome to Adaptive Complexity, where I write about genomics, systems biology, evolution, and the connection between science and literature, government, and society.

I'm a biochemist


... Full Bio

Eli Lilly and Merck are going to start reporting payments made to physicians.

How would you feel if you found out that your physician, who just prescribed you (or your child)that expensive new drug, has been receiving payments from the drug's manufacturer? Or that your physician has just attended a lavish "educational" conference at Lake Tahoe, sponsored by the drug's maker, and devoted largely to pushing the benefits of the drug?

The drug itself could be perfectly fine, but the conflict of interest would make most of us queasy. Which is why openness about payments by drug companies to physicians is a good thing.

It's possible that this move by Lilly and Merck won't go far enough in reporting all of the money they pay physicians, or making clear who gets payments, but it seems like a step in the right direction.

Comments

Hatice Cullingford's picture
So it fits well with open science as well, right??
adaptivecomplexity's picture
One open science issue to be resolved is control over drug company-funded publications. What happens when your drug trial results are negative? Negative research funded by big pharma is less likely to get published, according to a study reported in Nature a couple of years back - I see if I can find the reference.

Mike

Hank's picture
I guess we'd have to see what they mean by 'negative.' Nature is hardly neutral so anything related to funding and publishing will engender some skepticism about them. Witness one of the kookier science bloggers saying that a respected Nature journalist is a 'toadie' for asking if PLoS One is much good, given their pliable funding model (yet then glossing over their own marketing agreement with PLoS for free advertising, which was, apparently, irrelevant, since only other writers are in the bag) - so it has to go the other way too.

I wouldn't bother to publish results of failed experiments. I assume the vast bulk of experiments are failures in every science and they don't all get published. 3M and DuPont don't publish failures.

I know of a nutrition study review that said studies funded by industry were four to eight times as likely to reach conclusions 'in the financial interests' of sponsors.

But it defies belief that scientists getting corporate funding are on the take yet scientists getting government funding are ethically pristine. It mostly depends on what you want to believe.

Add a comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <sup> <sub> <a> <em> <strong> <center> <cite> <code> <TH><ul> <ol> <li> <dl> <dt> <dd> <img> <br> <p> <blockquote> <strike> <object> <param> <embed> <del> <pre> <b> <i> <table> <tbody> <div> <tr> <td> <h1> <h2> <h3> <h4> <h5> <h6> <hr> <iframe>
  • Lines and paragraphs break automatically.
  • Web page addresses and e-mail addresses turn into links automatically.
CAPTCHA
If you register, you will never be bothered to prove you are human again. And you get a real editor toolbar to use instead of this HTML thing that wards off spam bots.